XBI SPDR S&P Biotech ETF
- 92.410
- +3.280+3.68%
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Moderna And Merck Announced The First Presentation Of Results From A Planned Analysis From The Phase 2B KEYNOTE-942/mRNA-4157-P201 Study Of MRNA-4157 (V940) Plus Keytruda In Patients With Resected High-risk Melanoma Following Complete Resection (N=157)
With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable i
Breaking Down Moderna: 7 Analysts Share Their Views
During the last three months, 7 analysts shared their evaluations of Moderna (NASDAQ:MRNA), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, shed
Moderna Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 — Needham Reiterates → Hold 05/14/2024 -16.29% Evercore ISI Group → $120 Initiates Coverage On
Stocks Most Shunned by Hedge Funds and Mutual Funds
BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients With Normal C1-Inhibitor After Beginning ORLADEYO Treatment
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and functio
Here's How Much You Would Have Made Owning Novavax Stock In The Last 5 Years
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 5.74% on an annualized basis producing an average annual return of 18.97%. Currently, Novavax has a market capitalization of
Moderna's RSV vaccine received FDA approval as the first RNA vaccine other than COVID-19
The US Food and Drug Administration (FDA) approved Moderna's respiratory syncytial virus (RSV) vaccine on Friday for adults 60 and older. This is the company's second product to enter the US market. Analysts believe this approval is a win for Moderna, and the company urgently needs a new revenue stream as demand for its only commercial product, the COVID-19 vaccine, is falling sharply. According to information, Moderna's approval of the RSV vaccine is based on the results of advanced trials targeting the elderly, who are more likely to have severe RSV cases. According to US Disease Control
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
(NTRA) - Analyzing Natera's Short Interest
Natera's (NYSE:NTRA) short percent of float has fallen 5.87% since its last report. The company recently reported that it has 5.81 million shares sold short, which is 4.97% of all regular shares that
US Market Movers & Shakers in May: VFS, FSLR, MSTR and More
VinFast has seen a surge of 90.23% in May, while First Solar and MicroStrategy rose by 56.99% and 44.69% respectively.
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its portfolio, including a significant sell-off of Robinhood Markets Inc (NASDAQ:HOOD) shares. This move comes as Robinhood launches
Third Human Bird Flu Case Found in U.S.
HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling around 1% on Thursday.Shares of HP Inc. (NYSE:HPQ) rose sharply during Thursday's session following better-than-expected second-quarter financi
Today's Morning Movers and Top Ratings: HPQ, MRNA, PATH, AZN and More
Moderna stock increased by 2.9% as a Financial Times report indicated that the U.S. government is close to finalizing a deal to finance a late-stage trial of the company's pandemic bird flu vaccine.
Market Mover | Moderna Shares Surge 4% as U.S. Government Nears Deal to Fund Bird Flu Vaccine Trail
the US government is reportedly close to finalizing an agreement to provide funding for the late-stage trial of Moderna's bird flu vaccine.
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir Technologies Inc (NYSE
VIX Rises 8%, Treasury Yields Jump, Dow Plunges: Why Is Wall Street Wobbling Thursday?
It's been a rocky start to Thursday on Wall Street, with major U.S. equity indices and the eleven S&P 500's sectors all trading in the red. Volatility spiked amid rising investor anxiety over interest
Moderna's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled t
CareDx Responds To Natera's Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The '544 Patent.
CareDx Reiterates Position that it Does Not Infringe Natera's '544 PatentInjunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMapCareDx, Inc. (NASDAQ